Background: Lymphocytopenia is a prognostic factor in Hodgkin's disease. In diffuse large B-cell lymphoma (DLBCL), data are much less established, in spite of numerous reports on immune system-lymphoma interactions. This study addresses the prognostic value of blood lymphocyte subsets at diagnosis in DLBCL. 
introduction Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of lymphoma, accounting for 40% of lymphoid malignancies [1] . In this heterogeneous condition, the International Prognostic Index (IPI) based on clinical data (age, Ann Arbor tumor stage, serum lactate dehydrogenase (LDH), performance status (PS), and number of extranodal sites) was designed to identify patients at high risk of death [2] . However, a marked degree of heterogeneity in disease course still remains within each IPI group of patients [3] . This has generated a considerable amount of research aimed at discovering other prognostic markers.
A first field of research was aimed at a better understanding of the biology of the tumor itself, including study of cytogenetic abnormalities and their consequences on oncogenes, translating into cell cycle or apoptosis deficiencies and/or involved in Bcell differentiation abnormalities (reviewed in [4] ). A second field of investigation was focused on interactions between the host immune system and the tumor. An association between major histocompatibility complex class II expression by the tumor and prognosis was demonstrated [5] , as well as between the lymph node signature of reactive nonmalignant cells and favorable outcome [6] . However, research on tumor-infiltrating lymphocytes led to various, sometimes controversial results depending on studied subsets [7, 8] .
In spite of numerous reports on interactions between the immune system and lymphoma at the intratumoral level, no data have been reported in DLBCL patients on a simple evaluation of the immune status by enumerating peripheral lymphocyte subsets, as currently carried out in viral or iatrogenic acquired immune deficiencies.
In this study, we prospectively determined peripheral TCD4, TCD8, B, natural killer (NK) cell, and monocyte counts upon diagnosis in age-adjusted International Prognostic Index (aaIPI) 2 or 3 DLBCL patients, subsequently treated with anthracyclin-based induction chemotherapy followed by autologous stem-cell transplantation. We found that despite a frequent deficit in all lymphocyte subsets upon diagnosis, only the absolute NK cell count correlated with response to induction treatment and event free survival (EFS), and this independently of aaIPI.
patients and methods

patients and treatment
Patients recruited in this study were <60 years old, diagnosed with a DLBCL confirmed by pathological review, and presenting 2 or 3 adverse prognostic factors of aaIPI (clinical stage III-IV, LDH level above normal, Eastern Cooperative Oncology Group PS 2-4). These patients were included in the LNH98B3 therapeutic clinical trial of the Groupe d'Etude des Lymphomes de l'Adulte ( Figure 1 evaluation of response and event free survival
Evaluation of response at the end of the inductive cycles (D60) and of the consolidation regimen (D45) allowed to define patients in complete remission (CR), uncertain complete remission (uCR) or PR, according to Cheson criteria [10] . Nonresponders (NR) included patients achieving <50% reduction of the tumor burden, persistence of a progressive disease, treatment alteration or death during the inductive regimen.
EFS was calculated as the duration from the date of inclusion in the LNH98B3 trial to the date of the first event or stopping date (November 2004) or latest follow-up if the latter was anterior to the end point. Events were defined as follows: lymphoma progression during treatment, treatment alteration, lymphoma progression after treatment (PR patients), relapse (CR patients), and death from any cause, without disease progression.
The prognostic impact of peripheral blood cell subsets was assessed comparing responders (CR + uCR + PR) and NR. Patients in PR were merged with responders because this clinical trial involved the same therapeutic regimen for all responders, including PR. Besides, a multinomial logistic analysis comparing CR/uCR patients to PR patients and NR showed no discriminative power of cell counts between PR and CR/uCR groups (data not shown).
immunophenotyping
Absolute counts of peripheral blood main mononuclear subsets, i.e. CD4+, CD8+ T cells, B cells, NK cells, and monocytes, were prospectively carried out in patients upon diagnosis. Samples were analyzed in 17 laboratories, all members of the Groupe d'Etude Immunologique des Leucémies. The procedure was standardized as follows: absolute cell counts were derived directly from the flow cytometry data by using fluorescent beads of calibrated concentration (Ôsingle platformÕ technology), as recommended for low cell counts accuracy [11] . Mononuclear cells were defined as follows: lymphocytes were gated according to high-CD45 fluorescence intensity and low side scatter intensity; B cells were defined as CD19+ lymphocytes, CD4 T cells as CD3+CD4+ lymphocytes, CD8 T cells as CD3+CD8+ lymphocytes, NK cells as CD32CD16+ and/or CD56+ lymphocytes; monocytes were the CD14+ cells among the total leukocytes, i.e. CD45+ elements. Control reagent ImmunotrolÒ (Beckman-Coulter, Nyon, Switzerland) was used as quality control among participant laboratories to ensure homogeneity of measures.
statistical analysis
Comparisons of groups for quantitative data were done by Wilcoxon rank tests. Qualitative data were compared using the chi-square test or the Fischer's exact test when appropriate. For censored data, EFS curves were estimated by the Kaplan-Meier product-limit method and compared with the log-rank test. Multivariate analyses (Cox regression for censored data, logistic regression for treatment response data) were carried out to evaluate prognostic significance of the potential new predictors adjusted or not on known prognostic factors. In these analyses, log base 2 of lymphocyte subset counts were considered, according to their distribution characteristics (see Figure 2 ) and model checking analyses [12] . Use of a base 2 in the log transform allows interpreting the hazard ratio (HR) and odds ratio (OR) estimates as the ratio of risks linked to a two-fold increase (or decrease) of the untransformed predictor. P < 0.05 was considered to indicate statistical significance, and confidence intervals were computed with 95% coverage. All calculations were carried out with SAS software, version 8.20 (SAS Institute, Cary, NC) and survival library of R 2.1.1 package [13] . Figure 1) were recruited in the biological study. Among them, 13 were primary mediastinal B-cell lymphomas, nine T-cellrich B-cell lymphomas, and six were associated or developed from small B-cell lymphomas. Clinical characteristics of the patients at diagnosis are listed in Table 1 . Two-thirds of these original article Annals of Oncology 
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patients were >40 years old. According to inclusion criteria in the trial, patients presented with high tumor burden, as stated by III-IV Ann Arbor stages and LDH levels above maximal normal values in 98% and 92% of cases, respectively. Fortythree patients (31%) had a score 3 aaIPI. Fifty-five patients (40%) had a lymphopenia with lymphocytes at 700/ll or less.
Sixty-nine patients were randomly enrolled in the ACVBP arm and 71 in the AC/ACE arm. Following induction treatment regimen, 88 of 140 patients (62%) achieved a CR/uCR, 26 (19%) a PR, and 26 (19%) failed to respond. In all, 99 of 114 responders underwent an autograft (49 after ACVBP and 50 after AC/ACE). A second randomization was carried out in 85 patients, and 37 of them received rituximab after HDT (Figure 1) . The median follow-up of the analyzed population is 39 months.
The clinical characteristics were similar to those in the overall population of 476 patients enrolled in the LNH98B3 study, according to clinical presentation as well as to clinical outcome [9] . lymphocyte subsets upon diagnosis are quantitatively abnormal in a majority of patients Out of the 140 patients included in the biological study, 140 had an enumeration of their CD4, CD8, and B-cell subsets, while 136 and 131 had an enumeration of NK cell subsets and monocytes, respectively. As shown in Figure 2 , all studied subsets except for monocyte displayed quantitative abnormalities. It should be noted that CD4+ T cells, CD8+ T cells, and NK cells were no longer distributed according to a Gaussian distribution, but showed an increased frequency of low values as well as an increased heterogeneity of the higher values. Compared with reference ranges determined with the same methodology [14] , low median cell counts of 337, 211, and 104/ll were evidenced in the CD4+ T cells, CD8+ T cells, and NK cells subsets, respectively (Table 2) . Pathological examination of bone marrow was available in 136 patients. The counts of various peripheral blood lymphocyte subsets were similar in patients with (n = 33) or without (n = 104) bone marrow involvement. Similarly, no correlation was found between peripheral blood lymphocyte subsets count and PS or LDH level.
NK cell absolute count upon diagnosis is associated with clinical outcome
Absolute counts of CD4+, CD8+ T cells, B cells, NK cells, and monocytes were correlated with clinical outcome. Two parameters were used to assess the clinical course: (i) response to induction treatment, considering two groups, responders (CR + uCR + PR) and NR and (ii) EFS.
Univariate analysis showed that among subsets only NK cells were associated with disease outcome (Table 3) Therefore to evaluate the respective prognosis value of the NK cell count and the aaIPI, we carried out a multivariate analysis. It showed that NK cell count was associated with treatment response [OR (NK ·2) = 1.77 (1.24, 2.54), P = 0.002] By quantification on single platform [22] . To further assess the prognosis value of the peripheral NK cells in a clinical practice setting, we dichotomized the NK cell count. We chose a cut-off for NK cell counts at the lowest normal value, i.e. 80 NK cells/ll, thus dividing patients into those presenting with an abnormal, low NK cell count (51/136) and those with a normal/high NK cell count (85/136). Clinical and biological characteristics of both groups of patients are shown in Table 4 . It should be noted that no difference in CD4+ and CD8+ T cell or B cells enumeration was observed between these groups. Absolute count of NK cells <80 cells/ll was predictive of no response [OR (low versus high) = 4.8 (1.9, 12.2) (P < 0.001)] and of a shorter EFS [HR (low versus high) = 1.85 (1.14, 3) P = 0.01] (Figure 3) . In multivariate analysis, this parameter was independent from aaIPI [HR (low versus high) = 1.74 (1.07, 2.83) P = 0.03].
discussion
Peripheral blood lymphocyte subsets and monocyte counts were determined at diagnosis in 140 DLBCL patients with 2 to 3 adverse prognostic factors. More than half of the patients presented with lymphocytopenia involving the CD4+, CD8+ T, and NK cell subsets, but only NK cells counts correlated with induction treatment response and EFS.
Sixty one percent of patients under 60 presented severely decreased peripheral T and/or NK lymphocyte counts. To our knowledge, peripheral blood lymphocyte subset counts at diagnosis were never assessed in DLBCL. Lymphopenia is of uncertain origin. Tumor growth has recently been shown to impede functional maturation of NK cell precursors in a mouse model [15] . However, in our patients, no association between any subset deficiency and bone marrow involvement was observed, and lymphocyte subset counts were not associated with tumor burden. This also renders unlikely a potential disturbance of homeostatic signaling by tumor invasion of secondary lymphoid organs.
Global lymphocytopenia is a prognostic factor in Hodgkin's disease [16] . However, in non-Hodgkin's lymphomas, data are much less established [17, 18] . Using early death as criteria, either lymphocytopenia <700/ll [19] or leucocyte counts >10 000/ll [20] were reported as pejorative prognostic factors. In our series, using induction treatment response and EFS as prognostic criteria, lymphocytosis did not correlate with disease outcome.
We showed that the absolute NK cell counts are the only blood subset being significantly associated with disease outcome. We cannot exclude that NK cell deficiency is only a surrogate marker of disease severity: for instance, NK cell levels could reveal a stressed condition of the patients [21] , which would be the actual cause of the diminished antitumor response. However, this lymphocyte subset was first identified by its ability to kill tumor cells and since NK cells have indeed proven to be important effectors of antitumoral immunity [22] . In our particular setting, Street et al. [23] have shown in mice that NK cells are critical in innate immune surveillance of B-cell lymphomas. Accordingly, the association between a low number of circulating NK cells and a poor response to treatment can be envisioned according to two models. In a first model, the adjunction of chemotherapy, by alleviating the tumor burden, and/or modifying its effect on the immune system via dendritic cells [24] or Treg cells [25] , would restore at least partially the antitumor efficacy of NK cells. This cooperation NK/chemotherapy would be dependant on NK availability. Alternatively, low NK cell counts could mean that the cells left the peripheral blood compartment to infiltrate the tumor stroma but still lead to an inefficient response [26] , as hypothesized in the Ôhost responseÕ type of DLBCL which were shown to have no better outcome [27] . In this study, NK cell counts were carried out using the CD32CD16+/CD56+ identification, which encompasses all functional subsets of NK cells. Actually, circulating NK cells can be divided in two main subsets, cytolytic ones expressing dimly CD56, contrary to CD56bright cells which do not express cytotoxicity markers [28] and are more engaged in proinflammatory processes [29, 30] . Besides, peripheral NK cells diversely express activating (NCR, NKG2D), coactivating (2B4, DNAM-1), and inhibiting receptors (including NKG2D-CD94 and KIR molecules), whose combination might determine the antitumor ability [31, 32] . A better knowledge of these various NK cell subsets, defined according to their antitumor cytolytic abilities, could bring some clues to the host response type in DLBCL.
Moreover, in the field of DLBCL, the great majority of therapeutic trials designed over the past 3 years included an association of chemotherapy with anti-CD20 monoclonal antibodies [33] . Since antibody-dependent cellular cytotoxicity mediated by NK cells/monocyte macrophages remains a privileged mechanism of action of such drugs in nonHodgkin's lymphomas, patients presenting with low NK cell numbers could be doubly penalized, with a low NK cell activity and a low rituximab-dependent cytotoxicity. This is under investigation. Also, our results could be useful to avoid overinterpretation of data linking NK cells and mechanism of action of rituximab.
To sum up, we showed that the quantitative NK defect evidenced upon diagnosis in one-third of IPI 2-3 DLBCL patients was associated with induction treatment failure, indicating that NK cell subsets play a role in the response to induction treatment. These results support the potential interest of a treatment targeting the activation of NK cells, in particular, in new therapeutic designs including rituximab.
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